Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Beta-blocker use not linked to improved breast cancer prognosis

Key clinical point: There is no significant association between use of beta-blockers and improved clinical outcomes in women with breast cancer.

Major finding: Beta-blocker use was not associated with breast cancer recurrence (risk ratio [RR], 0.85; P = .17), breast-cancer-related mortality (RR, 0.83; P = .14), and all-cause mortality (RR, 1.01; P = .91).

Study details: A meta-analysis of 17 observational studies including 75,074 patients with breast cancer.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.


Li C et al. Biosci Rep. 2020 May 21. doi: 10.1042/BSR20200721.